Kyprolis sails through US advisory committee despite earlier FDA concerns
This article was originally published in Scrip
Executive Summary
It looks like smooth sailing for the US FDA to approve Onyx Pharmaceuticals' new multiple myeloma drug for patients in whom other treatments no longer are effective. The agency's panel of outside experts comprising the Oncologic Drug Advisory Committee (ODAC) on 20 June voted a resounding 11-0 (with one abstention) to back the product.